Pituitary and COVID-19 vaccination: a systematic review
Authors' conclusion
Despite the rarity of these events, our research findings suggest an association between COVID-19 vaccination and the subsequent development of pituitary diseases. The most common manifestations include hypophysitis with ADH deficiency, PA and SIADH, with symptoms typically emerging shortly after vaccine administration. Potential pathogenetic mechanisms include molecular mimicry, vaccine adjuvants and vaccine-induced thrombotic thrombocytopenia (VITT), with the presence of ACE2 receptors in the hypothalamus-pituitary system contributing to the process. These findings can aid in diagnostic and treatment decisions for patients presenting with these syndromes. Nevertheless, given the rarity of these events, safety and efficacy of the currently available COVID-19 vaccines remain robust and we strongly advocate continuing pursuing vaccination efforts.
Study context
- Population
- Patients with pituitary disease after COVID-19 vaccination; PubMed and Tripdatabase, January 1st, 2020 to February 12th, 202423 case reports
- Outcome
- Post COVID-19 vaccination pituitary disease
Pooled result
As reported in the abstract
- Hypophysitis
- 9 patients
- Pituitary apoplexy (PA)
- 6 cases
- SIADH
- 5 cases
- Isolated ACTH deficiency
- 2 cases
- Precipitating adrenal crisis
- 7 patients
- Pituitary tumor enlargement
- 1 patient
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →